Search

Your search keyword '"Cho, Eun Kyung"' showing total 709 results

Search Constraints

Start Over You searched for: Author "Cho, Eun Kyung" Remove constraint Author: "Cho, Eun Kyung"
709 results on '"Cho, Eun Kyung"'

Search Results

201. Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer

202. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)

209. Hypertensive Encephalopathy with Atypical Imaging Findings

210. A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09

211. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non–Small-Cell Lung Cancer: KCSG-LU05-04

212. Dynamic serial monitoring of EGFR mutations in plasma DNA samples in EGFR mutant NSCLC patients treated with EGFR TKI.

213. Safety of eribulin in Korean patients with metastatic breast cancer.

214. A phase II, single-arm, efficacy and safety study of poziotinib (NOV120101) in Korean patients with advanced or metastatic lung adenocarcinoma who have acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.

215. Final follow-up (f/u) results from RADIANT: A randomized double blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection in patients (pts) with stage IB–IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC).

216. Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).

218. Abstract P3-12-07: A multicenter randomized double-blind phase III clinical trial to evaluate the efficacy and safety of GCPGC, a novel pegylated G-CSF in patients receiving DA or TAC chemotherapy for breast cancer compared to peg-filgrastim

219. Abstract P3-10-04: A open-label, randomized, parallel, phase III trial to evaluate the efficacy and safety of Genexol®-PM compared to Genexol®(conventional paclitaxel with cremorphor EL) in recurrent or metastatic breast cancer patients

227. TRAIL Enhances Apoptosis of Human Hepatocellular Carcinoma Cells Sensitized by Hepatitis C Virus Infection: Therapeutic Implications

228. A retrospective study evaluating safety and feasibility of adjuvant chemotherapy with 6-week cycles versus 3-week cycles S-1 for patients with advanced gastric cancer curatively resected with D2 lymph node dissection.

229. A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell lung cancer (CCheIN).

234. Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset

235. A pilot study of low-dose capecitabine plus trastuzumab as first-line treatment for patients older than 75 years with HER2-positive advanced gastric cancer.

239. A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy

240. A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer

245. Evaluation of sarcopenia in small-cell lung cancer patients by routine chest CT.

246. Clinical and endocrine characteristics and genetic analysis of Korean children with McCune-Albright syndrome: a retrospective cohort study.

247. Global variation in copy number in the human genome

248. Prognostic Role of Serum Lactate Dehydrogenase Beyond Initial Diagnosis: A Retrospective Analysis of Patients with Diffuse Large B Cell Lymphoma

249. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy

250. Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma

Catalog

Books, media, physical & digital resources